Vidora of the tab. of p/o 3mg/0.03mg No. 84

Tablets film coated Vidora are shown for oral contraception.

Structure

1 blister contains 28 tablets (21 active tablets of yellow color and 7 tablets of placebo of white color).

Active ingredients: drospirenone, ethinylestradiol;

1 tablet, coated, yellow color supports a drospirenon of 3.0 mg and ethinylestradiol of 0.03 mg;

Excipients: lactose, starch corn, starch corn, krospovidonrlasdone XL-10 krospovidonrlasdone XL, K-30 povidone, polysorbate 80, magnesium stearate, Opadry yellow (polyethyleneglycol, polyvinyl alcohol, titan dioxide (E 171), talc, ferrous oxide yellow (E172)).

1 tablet, coated, white color (placebo) contains:

Excipients: lactose, K-30 povidone, magnesium stearate, Opadry II white (the polyvinyl alcohol (hydrolyzed a part), the titan dioxide (E 171), a macrogoal 3350, talc (E 553b)).

Contraindication

Combined Oral Contraceptives (COC) should not be applied in the presence of any diseases which are listed below. If any of diseases stated below appears for the first time during reception of COC, administration of medicament should be stopped immediately.

• venous thrombosis (a deep vein thrombosis, a pulmonary embolism) now or in the anamnesis;
• arterial thrombosis (for example a myocardial infarction) in the anamnesis or existence of the prodromal phenomena (for example stenocardia and the tranzitorny ischemic attack);
• a stroke in the anamnesis.

Existence of heavy or multiple factors of risk of arterial thrombosis:

• diabetes with symptoms from vessels;
• heavy arterial hypertension;
• heavy dislipoproteinemiya;
• hereditary or acquired tendency to venous or arterial thrombosis, including resistance to the activated protein of C (APC), insufficiency of antithrombin III, insufficiency of a protein With, insufficiency of a protein of S, a gipergomotsisteinemiya and anti-phospholipidic antibodies (anti-cardiolipin antibodies, lupoid anticoagulant);
• pancreatitis in the anamnesis if it is connected with a heavy gipertriglitseridemiya;
existence in the anamnesis of a serious illness of a liver, so far indicators of function of a liver are not normalized by
• ;
• heavy renal failure or sharp renal failure;
• existence in the anamnesis of tumors of a liver (benign or malignant);
• known or suspected tumors dependent on sex hormones (for example tumors of genitals or mammary glands);
• vaginal bleeding of not clear etiology;
• migraine with focal neurologic symptoms in the anamnesis;
• hypersensitivity to any active ingredient or any of excipients;
• known or suspected pregnancy.

Route of administration

Method of administration: oral administration.

At the correct application of the combined oral contraceptives (COC) the extent of failures makes about 1% a year. At the admission of reception of tablets or their wrong application extent of failures can grow.

needs to take the Pill every day at the same time, if necessary with a small amount of liquid, according to the order specified on the blister packing.

Pill is taken continuously. One pill is taken daily within 28 days in a row. Reception of tablets from each following packing begins next day after reception of the last tablet from the previous packing.

Feature of application

Pregnant

It is contraindicated.

Drug is shown by

for application on doctor's orders only after approach steady to periods.

Drivers

. At the women applying the COOK no influence on ability to steer vehicles and to work with mechanisms was observed.

Overdose

by this time any experience on overdoses of drospirenon / ethinylestradiol is absent. On the basis of the general experience of application of the combined oral contraceptives allocate symptoms which can be observed at overdose of active tablets: nausea, vomiting, and young girls have an insignificant bleeding from a vagina. No antidotes exist and further treatment has to be symptomatic.

Side effects

Emotional lability, a headache, pain in a stomach, an acne, mammary gland pain, increase in mammary glands, a dysmenorrhea, a metrorrhagia, increase in body weight.

Interaction

For establishment of possible interaction with medicines which are appointed along with the COOK is recommended to study the instruction for use of this medicine.

Use of contraceptive steroids can affect results of certain laboratory analyses, including biochemical parameters of function of a liver, thyroid gland, adrenal glands and kidneys, indicators of content in blood plasma of proteins (carriers), for example, of the globulins connecting corticosteroids, and indicators of lipids / fractions of lipoproteins, parameters of carbohydrate metabolism and also parameters of coagulation and a fibrinolysis. In general these changes remain within normal values. Drospirenon causes increase in activity of renin in plasma of blood and levels of Aldosteronum in blood plasma by insignificant antimineralokortikoidny activities.

to Store

out of children's reach at a temperature not above 25 °C.

Expiration date - 3 years.